Advice
in the absence of a submission from the holder of the marketing authorisation:
peginterferon alfa-2a (Pegasys®) is not recommended for use within NHSScotland.
Indication under review: as monotherapy in adults for the treatment of essential thrombocythaemia.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result, we cannot recommend its use within NHSScotland.
Download detailed advice376KB (PDF)
Medicine details
- Medicine name:
- peginterferon alfa-2a (Pegasys)
- SMC ID:
- SMC2937
- Indication:
Monotherapy in adults for the treatment of essential thrombocythaemia.
- Pharmaceutical company
- pharmaand GmbH (pharma&)
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 11 May 2026